<DOC>
	<DOCNO>NCT00016393</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . PURPOSE : Phase II trial study effectiveness BMS-247550 treating patient prostate cancer respond hormone therapy .</brief_summary>
	<brief_title>BMS-247550 Treating Patients With Prostate Cancer That Has Not Responded Hormone Therapy</brief_title>
	<detailed_description>OBJECTIVES : - Determine prostate-specific antigen response BMS-247550 patient hormone-refractory prostate cancer . - Determine overall survival progression-free survival rate patient treat drug . - Determine objective response rate ( confirm unconfirmed complete partial response ) patient measurable disease treat drug . - Evaluate qualitative quantitative toxic effect regimen patient . OUTLINE : This multicenter study . Patients receive BMS-247550 IV 3 hour day 1 . Treatment repeat every 21 day absence disease progression unacceptable toxicity . Patients achieve complete response ( CR ) receive 2 additional course beyond CR . Patients follow every 3 month 1 year every 6 month 2 year . PROJECTED ACCRUAL : A total 25-45 patient accrue study within 5-9 month .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Hormones</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm adenocarcinoma prostate Stage D1 D2 disease ( T4 , N0 , M0 ; T , N13 , M0 ; T , N , M1 ) Unresponsive refractory prior hormonal therapy least 1 follow : Progression unidimensionally measurable lesion outside prior radiation port Progression nonmeasurable disease ( e.g. , bone scan ) Rising prostatespecific antigen ( PSA ) least 2 consecutive measurement take least 7 day apart PSA least 5 ng/mL No brain metastasis PATIENT CHARACTERISTICS : Age : Not specify Performance status : Zubrod 02 Life expectancy : Not specify Hematopoietic : Absolute granulocyte count least 1,500/mm^3 Platelet count least 100,000/mm^3 Hepatic : Bilirubin great upper limit normal ( ULN ) SGOT SGPT great 2.5 time ULN Renal : Creatinine great 2.0 mg/dL OR Creatinine clearance least 40 mL/min Other : No malignancy within past 5 year except adequately treat squamous cell basal cell skin cancer , carcinoma situ , stage I II cancer complete remission No concurrent significant active illness would preclude study participation Recovered major infection Fertile patient must use effective contraception PRIOR CONCURRENT THERAPY : Biologic therapy : At least 28 day since prior biologic therapy recover No 1 prior biologic ( noncytotoxic ) therapy No concurrent biological response modifier Chemotherapy : No prior chemotherapy disease No concurrent chemotherapy Endocrine therapy : See Disease Characteristics At least 28 day since prior flutamide ketoconazole At least 42 day since prior bicalutamide nilutamide No concurrent hormonal therapy , except luteinizing hormonereleasing hormone therapy No concurrent corticosteroid Radiotherapy : See Disease Characteristics Prior radiotherapy le 30 % bone marrow allow No prior strontium chloride Sr 89 samarium Sm 153 lexidronam pentasodium At least 28 day since prior radiotherapy recover No concurrent radiotherapy Surgery : Recovered prior surgery Prior orchiectomy allow Other : No concurrent unconventional therapy ( e.g. , St. John 's Wort , PCSPES , herbal remedy prostate cancer ) Not plan begin bisphosphonate therapy ( patient already receive bisphosphonates eligible provide progressive disease )</criteria>
	<gender>Male</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2004</verification_date>
	<keyword>adenocarcinoma prostate</keyword>
	<keyword>stage IV prostate cancer</keyword>
	<keyword>recurrent prostate cancer</keyword>
</DOC>